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Summary
Platelet gel improves left ventricular mechanical function in the 
ischemic reperfused Langendorff rabbit heart, decreases ROS production 
and mitochondrial depolarization in HUV-EC cells (Homo sapiens, 
human Umbilical Vein Endothelium) in vitro, protects catalase and 
superoxide dismutase when prepared using nanosecond pulsed electric 
fields rather than bovine thrombin and decreases the metalloproteinase 
MMP-2 and increases the metalloproteinase inhibitor TIMP-1 in H9c2 
cells (Rattus norvegicus H9c2 cardiac myoblast cells) in vitro.
Introduction
In patients admitted to a hospital with myocardial infarction, 
some of the myocardial tissue is irreversibly damaged by necrosis, 
but a larger part is under ischemic stress and may still be saved by 
appropriate intervention. It is essential to restore coronary flow to the 
ischemic region (reperfusion), but if no additional measures are taken, 
reperfusion causes the production of reactive oxygen species (ROS), 
which can lead to substantial tissue death (reperfusion injury) [1]. 
Autologous Platelet-rich plasma (PRP) or platelet gel is emerging 
as a biological tool to reduce cardiovascular reperfusion injury in 
animal experiments [2]. PRP is made from an animal’s own whole 
blood (autologous). The platelets are concentrated and the release of 
growth factors from the platelets is induced, typically by combining 
the platelet concentrate with bovine thrombin and calcium. The 
resulting “activated” PRP contains a super-physiological concentration 
of growth factors, cytokines, and other proteins [3]. Injecting it into 
the myocardium after infarction and prior to reperfusion significantly 
improves left ventricular mechanical function during reperfusion in 
vivo [4] in rabbit hearts and promotes angiogenesis and mitogenesis 
in the sheep heart when injected 3 weeks after coronary ligation and 
evaluated 9 weeks later [5]. In addition to the growth and healing 
promoting proteins, PRP provides a scaffold that traps cells such as 
stem cells in the region of injury giving the proteins time to help the 
cells differentiate into cardiac myocytes. 
Several problems have so far precluded the use of activated PRP in 
the cardiovascular system of patients: 1) injecting a PRP that contains 
red blood cells into the heart may lead to thrombi that can cause 
stroke or myocardial infarction; 2) thrombin used to prepare PRP can 
cause serious bleeding abnormalities in some patients who develop 
antibodies against certain clotting factors as well as other adverse 
events 3 (thrombin, itself, causes the generation of ROS and 4) lack of a 
mechanism explaining the mode of action of activated PRP.
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Abstract
Background: The prompt restoration of blood flow (reperfusion) to the ischemic myocardium after an acute 
myocardial infarction is critical to the survival of non damaged heart tissue. However, reperfusion is responsible for 
additional myocardial damage. Our objective was to investigate the role of autologous platelet rich plasma or platelet 
gel prepared using nanosecond pulsed electric fields (nsPEFs) in improving left ventricular mechanical function after 
ischemic reperfusion.
Methods: The hearts of nine adult female New Zealand White rabbits were perfused using the Langendorff 
model. The hearts were exposed to global ischemia for 30 min and reperfused for 60 min. The hearts were injected 
with 600 µl of platelet gel supernatant prepared using nsPEF or platelet gel supernatant prepared using bovine 
thrombin or with bovine serum albumin (BSA) which served as our control. HUV-EC cells or H9c2 were used in 
vitro to determine the effect of platelet gel on ROS formation and mitochondrial depolarization using flow cytometry. 
Metalloproteinase’s and their inhibitors were assessed using western blot analysis. HPLC was used to identify the 
presence of endogenously secreted antioxidants in the platelet gel.
Results: Platelet gel improved left ventricular mechanical function of the heart, reduced ROS formation and 
reduced mitochondrial depolarization. Platelet gel also decreased MMP-2 and increased TIMP-1. Catalase and 
superoxide dismutase were preserved at greater concentrations in the platelet gel made using nsPEFs than in the 
platelet gel made with bovine thrombin. 
Conclusion: Platelet gel is cardioprotective to non- ischemic reperfused cardiac tissue after acute myocardial 
infarction and reperfusion.
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We have recently modified our production of PRP in two important 
ways: First, we have a new effective and safe way to activate PRP (without 
using thrombin), using nanosecond pulsed electric fields (nsPEFs) for 
the release of the stored growth factors. PRP activated by nsPEFs (ns-
PRP) is similarly effective, if not more so, to thrombin-activated PRP 
(t-PRP). Second, we have eliminated the presence of red blood cells 
(RBC) in what we call our “PRP-supernatant”. 
In this study we investigated the effect of the ns-PRP supernatant 
with that of a thrombin activated PRP supernatant both in situ using 
the ischemic and reperfused Langendorff heart and in vitro using HUV-
EC- Homo sapiens, human Umbilical Vein Endothelium (PCS-100-013 
™ ATCC; Manassas, VA, USA) cells or H9c2 (Rattus norvegicus H9c2 
cardiac myoblast) cells. We also examined whether freezing the PRP 
supernatant at -20°C had any effect of its effectiveness in vitro or in situ.
Materials and Methods
The protocols used in all studies involving animals were approved 
by the Animal Care and use Committee at Old Dominion University 
and in accordance with the Guide for the Care and Use of Laboratory 
Animals, 8th edition, 2011 National Research Council.
Preparation of Platelet Rich Plasma (PRP)
PRP was prepared as described by Harvest Technologies 
(Plymouth, MA). Sixty ml of whole blood was withdrawn from a donor 
rabbit using a sterile syringe containing 6 ml of ACD-A anticoagulant. 
A SmartPRep®-2 Platelet Concentrate System and a sterile processing 
disposable pack (Terumo Cardiovascular Systems, Ann Arbor, MI) 
were used to prepare PRP and platelet poor plasma. The processing 
disposable was centrifuged for 14 min to separate the blood components 
from the plasma. Platelet poor plasma was used to re-suspend the 
concentrated platelets to a final volume of 7 ml. 
Hematological analysis of rabbit whole blood used to prepare PRP 
was analyzed using a HESKA Diagnostic System (Loveland, Colorado). 
The PRP had an average platelet count of 295×103/µl. The Harvest 
Technology System concentrator (Harvest Technologies, Plymouth, 
MA) concentrated the platelets in the whole blood 4-7 times providing 
a platelet concentrate between 1180×103/µl and 2065×103/µl of platelets.
Nanosecond Pulse Electric Field (nsPEF) and the pulse 
generator 
Nanosecond pulse electric fields are ultrashort, high voltage 
pulsed electric fields. The pulses are of short duration and they affect 
intracellular as well as extracellular structures (membranes) and 
functions (cell signaling). Nanopulses convey intense, high power 
(megawatts) but low energy (joule) electric fields to platelets. nsPEFs 
charge cellular membranes of platelets and create a pore [6,7].
Platelets were activated using a 300 ns pulse generator. The 300 ns 
pulse generator used for these studies was described by Zhang et al. 
[6] and Schoenbach et al. [7]. The electrical pulses were applied to an 
electroporation cuvette with an electrode gap of 0.2 cm. The aluminum 
cuvette plate electrode, had an area of 1 cm2 for the 0.2 cm gap cuvette. 
The shape and amplitude of the pulse voltage, was monitored using a 
500 MHz oscilloscope. 
Activation of platelets using nsPEFs
 The electrical pulses were applied to the PRP concentrate in the 
presence of 2 mM calcium in sterile electroporation cuvettes. The PRP 
concentrate (1 ml) was exposed to 5 pulses at an electric field of 30 kV/
cm for a duration of 300 ns. 
Activation of platelets using bovine thrombin
 Preparation of a bovine thrombin activated platelet gel was prepared 
as described above in Preparation of Platelet Rich Plasma (PRP) with 
the exception that thrombin was used as the platelet activator. For 
comparison, t-PRP was activated using an APC+™ activator (Harvest 
Technology, Plymouth, MA) made by combining bovine thrombin 
with 10% calcium chloride at a ratio of 1:10. The thrombin –calcium 
combination was added to the platelet concentrate and 600 µl of t-PRP 
supernatants or BSA (control) was injected into the left ventricular 
heart muscle in the Langendorff model. 
Method used for making Platelet Gel Supernatant
 After the PRP was activated using nsPEFs or bovine thrombin as 
previously described it was kept at room temperature for 10 min or 
until the clot was formed. The activated PRP (clot) was centrifuged at 
14,000 RPM for 10 min to pellet down any red blood cells and platelet 
fragments. The supernatant was removed and used fresh or it was frozen 
for 24 hr at -20°C then used in the Langendorff heart or in in vitro 
experiments. For all experiments using frozen PRP, the supernatant was 
thawed only once.
Ischemic Reperfusion Heart Experiments (Langendorff 
Model)
Nine female New Zealand White rabbits (3.5-4.0 kg, CoVance, 
Denver, PA) were sedated by administering acepromazine (10 mg/kg) 
and ketamine (25 mg/kg), intramuscular. A surgical plane of anesthesia 
was induced by allowing the animal to breathe isoflurane and oxygen. A 
midline thoracic-abdominal incision was made. Sixty milliters of whole 
blood was removed from the inferior vena cava for the preparation 
of platelet gel. The heart was then quickly removed and placed into a 
modified Tyrode's solution chilled to 0-4°C. The heart was mounted 
as previously described [8]. Briefly, after mounting, a balloon catheter 
attached to a pressure transducer was inserted into the left ventricle and 
inflated. Left ventricular systolic and diastolic pressures were recorded 
every 10 seconds through a polyvinyl catheter using a COBE CDX III 
transducer and Micro-Med 100 Blood Pressure Analyzer (Louisville, 
KY). The preparation was allowed to beat spontaneously and permitted 
to equilibrate for 15 min prior to initiation of the experimental protocol. 
The heart was given 10 min to re-stabilize prior to closing off flow 
through the aortic cannula to create global ischemia. This ischemia was 
maintained for 30 min with the heart encased in a heated water jacket 
and maintained at 37°C. At the end of the 30-min ischemic period the 
aortic cannula was re-opened and the heart reperfused for 60 min. All 
injections (ns-PRP (600 µl) or t-PRP (600 µl) or our control BSA (600 
µl) were injected into the myocardium 10 min prior to reperfusing the 
heart. All data were normalized to a baseline of 100% and stated as the 
mean ± SD.
In Vitro ROS production in the presence and absence of PRP 
supernatant using flow cytometry
These cell culture experiments were performed using human 
umbilical vein endothelial cells, termed HUV-EC, over a three day 
period. HUV-EC are primary cells that are considered 'primary cultures 
', in the truest sense; meaning that they have been preserved after only 
1 to 3 passages from the initial source material (ATCC; Manassas, 
VA). The cells were grown in sterile T- 75 cm2 tissue culture flasks in 
an incubator at 37°C and 5% atmospheric CO2. Cell culture media 
consisted of 15 mL Dulbecco’s Modified Eagle’s Medium™ (DMEM) 
(Mediatech, Inc, Manassas, VA) containing 10% fetal bovine serum 
(FBS, Atlanta Biologicals, Inc., Lawrenceville, GA). Once the cells 
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or superoxide dismutase enzymatic activity using assay kits described 
below. 
Catalase (CAT) assay kit: Cayman’s CAT assay kit (Ann Arbor, 
MI) was used to measure the concentration of CAT. This assay used 
the peroxidatic function of CAT for determination of enzyme activity. 
The method is based on the reaction of the enzyme with methanol in 
the presence of an optimal concentration of H2O2. The formaldehyde 
produced was measured colorimetrically with Purpald as the 
chromogen. The HUV-EC cells were homogenized, centrifuged, and 
the supernatant removed and assayed per manufacturer instructions.
Superoxide Dismutase (SOD) assay kit: Cayman’s SOD assay 
kit was used to measure the concentration of SOD. This kit used a 
tetrazolium salt for detection of superoxide radicals generated by 
xanthine oxidase and hypoxanthine. The assay measures all three types 
of SOD. The HUV-EC cells were homogenized, centrifuged, and the 
supernatant removed and assayed per manufacturer instructions.
Western blot analysis
To determine the effect of platelet gel on the proteins MMP-2 
and TIMP-1 we used H9c2 cells in culture. The protein concentration 
in each sample was determined using a BCA protein assay (Thermo 
Fisher Scientific, Rockford, IL). Rabbit monoclonal MMP-2 and rabbit 
polyclonal TIMP-1 primary antibodies (Abcam, Cambridge, MA) were 
diluted 1:2 in blocking buffer. Goat anti-rabbit secondary antibodies 
conjugated with an infra-red fluorophore IRDye-800CW (LI-COR 
Biosciences) was diluted 1:5000 in blocking buffer. The blots were 
treated with the primary antibodies at 4°C overnight, washed 4 times 
(5 min each) in PBST with 0.1% Tween-20, treated with secondary 
antibodies for 1 hr, and washed again. The membranes were imaged 
using an Odyssey 9120 Infrared Imaging System (LI-COR Biosciences) 
in the 700 nm channel. The images were quantified using MetaMorph 
software. Data was normalized to the housekeeping protein (β Actin).
Statistical Analysis
The Langendorff heart data were analyzed using an analysis of 
variance corrected for repeated measures and the data stated as the mean 
± standard deviation. The Tukey or Student-Newman-Keuls Post-Hoc 
Tests were used to determine which groups were statistically different 
from each other. ROS or mitochondrial depolarization experiments 
were repeated at least five times and analyzed using a Student-T test. 
Data are stated as the mean ± SD. Data were considered significant at 
p<0.05.
Results
Figure 1 shows work function (pumping ability) of the left ventricle 
in the Langendorff rabbit hearts treated with ns-PRP supernatant (n=3) 
made using nsPEFs, t-PRP supernatant (n=3) or bovine serum albumin 
(BSA) (n=3) which was our control. Work function was calculated by 
multiplying left ventricular pressure times heart rate. The data were 
then normalized to a baseline of 100%. Thirty min into reperfusion 
the ns-PRP treated hearts had a significantly greater left ventricular 
pumping function than the hearts treated with t-PRP or BSA. The 
pumping activity remained significantly greater in the ns-PRP treated 
hearts after 60 min of reperfusion. Left ventricular pressure and heart 
rate are shown in Tables 2 and 3, respectively.
Figure 2 shows the effect of PRP which contained RBCs (ns-PRP) 
made fresh on the day of treatment or frozen for 24 hr before use or 
ns-PRP supernatant on mitochondrial depolarization No studies 
were performed using bovine thrombin. The percent of healthy (non-
reached 85-95% confluency, approximately 800,000 HUV-EC cells were 
transferred onto a sterile T-25 cm2 tissue culture flask on day 1. On day 
2, after a 24 hr incubation in DMEM the cells were treated with fresh 
DMEM and served as controls or with 3.5 ml of DMEM containing ns-
PEF or bovine thrombin activated PRP (not the supernatant) (0.525g) 
or PRP supernatant fresh or frozen. The cells were then returned to the 
incubator for 24 hours. On day 3 ROS detection analysis was performed 
using Flow Cytometry (BD FACSAria, San Jose, CA). The cells were 
washed with fresh cell culture medium, trypsinized and suspended in 
cell culture media. They were then loaded with 20 µM concentration 
of CM-H2DCFDA dye solution per manufacturer instructions 
(Invitrogen-Molecular Probes, Eugene, OR), then placed in the dark 
at 37°C for 1 hr. After the 1 hr loading period the cells were stimulated 
for 5 min with 0.15% hydrogen peroxide (H2O2) and analyzed for ROS 
production using Flow Cytometry. 
Mitochondrial depolarization analysis in HUV-EC cells 
treated with PRP and analyzed using flow cytomerty 
These experiments were also performed over a 3 day period using 
HUV-EC cells in culture. During the 1st two days the cells were treated 
as described above for ROS analysis. Using nsPEFs to activate platelets 
we investigated the effect of PRP (which contained red blood cells 
along with the growth factors) prepared fresh on the day of treatment 
or frozen for 24 hr then used to pretreat the cells as well as PRP 
supernatant made fresh on the day of treatment or frozen for 24 hr then 
used to treat cells. None of these experiments were performed using 
bovine thrombin-all PRP supernatants were prepared using nsPEFs. 
On day 3 of the experiment the media was removed and discarded. 
Cells were stimulated with either 0, 0.03 (8.8 mM), 0.07 (20.5 mM), or 
0.15% (44 mM) of H2O2 in DMEM growth medium at 37°C in a 5% CO2 
incubator for 15 minutes. The cells were then washed in fresh media, 
trypsinized and re-suspended in media. The media was discarded after 
centrifugation at 200 g for 10 minutes. The cells were again re-suspend 
in 0.5 mL of 1X MitoPTTM JC-1 buffer solution (ImmunoChemistry 
Technologies, LLC, Bloomington, MN) and incubated at 37°C in a 
5% CO2 incubator for 15 minutes. Following this loading period, the 
cells were washed with and re-suspened in assay buffer. The changes 
in mitochondrial membrane potential were evaluated using a flow 
cytometer. A membrane-permeant JC-1 dye was used per manufacturer 
instructions (Immuno-Chemistry Technologies, Bloomington, MN), 
to assess mitochondrial health/depolarization in cells pretreated with 
PRP supernatant or cell culture media only (control). JC-1 dye exhibits 
potential-dependent accumulation in mitochondria, indicated by a 
fluorescence emission shift from green (~529 nm) to red (~590 nm). 
When cells stained with MitoPT™ JC-1 were analyzed with the flow 
cytometer, depolarization was measured by monitoring the amount 
of red fluorescence. Healthy cells fluoresced red. However, as the 
mitochondria depolarized the amount of red fluorescence decreased. 
HPLC analysis of PRP supernatant
The content of ns-PRP or t-PRP was subjected to chromatography 
over gel filtration Superdex 200 10/300 column (GE Healthcare Life 
Sciences, Piscataway, NJ) and equilibrated with Assay Buffer containing 
10mM HEPES, 140 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 10 mM 
Glucose, pH=7.3. One milliliter of the each sample was loaded onto a 
column and eluted in Assay Buffer at a flow rate 0.6 ml/min. The 0.6 ml 
fractions were collected between 6-24 ml of elution volume. Every five 
fractions were combined and concentrated to 0.5 ml (Amicon Ultra-4, 
Millipore, Billerica, MA). Fractions 11-20 and 15-29 collected between 
10-20 ml of elution volume were chosen for further analysis for catalase 
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depolarized) versus depolarized cells pretreated with the various 
forms of PRP in the absence of H2O2 was significantly greater in all 
cases except the frozen nsPRP. However, the cells pretreated with PRP 
and stimulated with 0.15% H2O2 had significantly less mitochondrial 
depolarization. These data suggest that PRP, whether freshly prepared 
or frozen and thawed may have a protective effect on the mitochondria 
of the HUV-EC cells and are consistent with our previous findings 
using H9c2 cells [4] suggesting that this effect is not cell specific. 
Figure 3 shows a comparison of the effect of fresh on the day of 
treatment or frozen ns-PRP on ROS generation in HUV-EC cells 
stimulated with 0.15% H2O2. Again, cells pretreated with PRP (fresh, 
frozen or supernatant) and stimulated with H2O2 generated significantly 
less ROS than cells treated with cell culture media only. These data are 
also consistent with our previous findings in H9c2 cells [4] and suggest 
that this response is not cell specific.
The degree of heart function that remains after a myocardial 
infarction is partly due to the degree of degradation of the extracellular 
matrix (ECM) of the heart by enzymes such as the metalloprotienases. 
In this study we asked the question whether PRP modulated the 
metalloprotienases (MMPs) designed to degrade the ECM and/or 
their inhibitors (TIMPs) which are designed to prevent or control the 
degree of degradation by the MMPs. We pretreated H9c2 cells with 
PRP, stimulated them with 1% H2O2 and analyzed the response using 
Western Blot Analysis. Thrombin prepared PRP was not used in these 
studies. Figures 7A and B are representative examples of changes in the 
metalloprotinease inhibitor TIMP-1 and the metalloprotinease MMP-
2. We also analyzed changes in MMP-9 and TIMP-4 but were unable to 
detect a change from baseline values (data not shown). Baseline levels of 
MMP-2 were greater than baseline levels of the tissue inhibitor TIMP-
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Figure 1: Comparison of left ventricular work function in the Langendorff heart 
treated with PRP prepared with nsPEFs  (nsPEF-PRP; n=3), bovine thrombin 
(t-PRP; n=3) or bovine serum albumin (BSA; n=3) as our control. Baseline 
values were normalized to 100%. Work function was calculated by multiplying 
left ventricular pressure times heart rate.   Work function was significantly 
greater in the hearts treated with nsPEF-PRP than hearts treated with t-PRP 
or BSA.   * p<0.05 nsPEF-PRP compared to thrombin- PRP or Control (BSA). 
Data are stated as mean ± SD. The x axis is time after 30 min of global 
ischemia and during reperfusion. Time 0 is the 15 min baseline (control) period 
before ischemia.
H9c2 Cells 
Alone
H9c2 Cells + 1% 
H2O2
H9c2 Cells + 
PRP
H9c2 Cells + 
PRP + 1% H2O2
TIMP-1 0.145 0.3007 2.238 0.985
MMP-2 5.06 5.83 0.099 0.097
Table 1: Quantative analysis of western blot for TIMP-1 and MMP-2 using an 
Odyssey Infrared Imaging System. H2O2=hydrogen peroxide, PRP=platelet rich 
plasma, TIMP-1- metalloproteinase inhibitor, MMP-2- metalloproteinase.
Time (min) Fresh PRP (n=3)
Frozen PRP 
(n=3)
BSA (control) 
(n=3)
Thrombin 
PRP (n=3)
0 100 ± 0 100 ± 0 100 ± 0 100 ± 0
10 75 ± 15 78 ± 12 92 ± 26 73 ± 8
20 86 ± 17 91 ± 8 106 ± 28 93  ± 18
30 91 ± 19 94 ± 5 114 ± 25 101 ± 18
40 92 ± 20 94 ± 5 117 ± 24 105 ± 18
50 91 ± 20 93 ± 5 118 ± 23 107 ± 17
60 90 ± 20 90 ± 7 108 ± 10 111 ± 21
Table 2: Left ventricular Systolic Pressure in Langendroff hearts treated with 
nsPRP or Thrombin PRP supernatant or BSA (control) measured using a COBE 
CDX III transducer and Micro-Med 100 Blood Pressure Analyzer.  Time 0 is the 
control period prior to ischemia.
Time (min) Fresh PRP (n=3)
Frozen PRP 
(n=3)
BSA (control) 
(n=3)
Thrombin 
PRP (n=3)
0 100 ± 0 100 ± 0 100 ± 0 100 ± 0
10 92 ± 3 116 ± 20 85 ± 5 96 ± 11
20 91 ± 12 109 ± 20 80 ± 10 90 ± 16
30 96 ± 19 114 ± 20 76 ± 12 89 ± 18
40 97 ± 24 121 ± 17 75 ± 13 90 ± 16
50 98 ± 25 125 ± 16 74 ± 14 89 ± 13
60 98 ± 27 128 ± 15 73  ± 9 88 ± 10
COBE CDX III transducer and Micro-Med 100 Blood Pressure Analyzer.  Time 0 is 
the control period prior to ischemia.
Table 3: Left ventricular Heart Rate in Langendroff hearts treated with nsPRP or 
Thrombin PRP supernatant or BSA (control) measured using a COBE CDX III 
transducer and Micro-Med 100 Blood Pressure Analyzer.  Time 0 is the control 
period prior to ischemia.
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Figure 2: Comparison of the effect of fresh or frozen ns-PRP on mitochondrial 
depolarization in HUV-EC cells stimulated with H2O2.   * compares the % of 
non-depolarized (healthy) to depolarized (damaged) mitochondria  pretreated 
with fresh nsPEF-PRP and stimulated with 0.15% H2O2; p<0.01. ** compares 
the % of non-depolarized (healthy) to depolarized (damaged) mitochondria 
pretreated with fresh nsPEF-PRP supernatant and stimulated with 0.15% 
H2O2; p<0.01. ***compares the % of non-depolarized (healthy) to depolarized 
(damaged) mitochondria  pretreated with frozen nsPEF-PRP and stimulated 
with 0.15% H2O2; p<0.002.   Data are stated as mean ± SD. N=the number of 
separate experiments.
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1. We are unable to explain why basal levels of MMP-2 were so high. 
However, when the cells were treated with PRP there was a drastic fall 
in MMP-2 and an increase in TIMP-1. Stimulation of the cells with 1% 
H2O2 was not associated with an increase MMP-2 but was associated 
with an increase in TIMP-1. When exposed to H2O2 TIMP-1 decreased 
slightly and may be the result of its utilization in the inhibition of MMP-
2. Table 1 provides a quantitative description of the data. 
Discussion
Ischemic reperfusion is a major cause of myocyte loss in the heart. 
Significant loss of cardiac myocytes after ischemia and reperfusion can 
lead to extensive dysfunction of the left ventricle and eventually loss of 
life. While clinicians have tools available to re-open closed or clogged 
coronary vessels, there is still no reliable therapeutic strategy for 
protecting the stressed, non-ischemic myocytes from a phenomenon 
called “reperfusion injury”. The term reperfusion injury describes a 
number of events that result in myocyte damage through myocardial 
stunning (persistent mechanical dysfunction despite the restoration of 
blood flow; usually reversible), the no-flow phenomenon after opening 
an infarcted artery; reperfusion arrhythmia and irreversible injury of 
the myocardium (necrosis) [9]. The non-ischemic myocytes adjacent 
to the infarcted area are placed under oxidative stress and many of the 
undamaged cells may become apoptotic and die thereby increasing the 
size of the infarcted area of the heart. 
 We investigated the strategy of using the supernatant of platelet 
rich plasma or platelet gel to assess its effect on left ventricular function 
in the ischemic reperfused heart both in vivo [4] and in situ (Figure 1). 
In both cases, left ventricular function was significantly improved in 
the hearts treated with platelet gel, particularly the gel prepared using 
nsPEFs. Whether the platelets are activated with nsPEFs or bovine 
thrombin appears to play a role in the effectiveness of the platelet gel. 
We show that the work performance of the Langendorff hearts treated 
with platelet gel prepared using nsPEFs was significantly greater than 
the hearts treated with platelet gel made with bovine thrombin. We 
have previously reported improvement in left ventricular mechanical 
function in the rabbit heart in vivo [4]. The hearts were infarcted, 
treated with platelet gel and stressed with dobutamine 14 days post 
infarct. In these studies not only was positive and negative dp/dt better 
in the platelet gel treated hearts but infarct size was also smaller [4]. 
These data suggest that the hearts treated with PRP supernatants made 
using nsPEFs had a better work performance than either of the other 
two groups. 
There are several possibilities that may explain why left ventricular 
function was enhanced to a greater extent in the hearts treated with 
platelet gel both in vivo and in situ in general and with platelet gel made 
with nsPEFs specifically. First, we demonstrate in this study using HUV-
EC cells (endothelial cells) in vitro and previously in vitro using H9c2 
(Rattus norvegicus H9c2 cardiac myoblast) cells that pretreatment with 
platelet gel reduced the amount of reactive oxygen species produced 
by the cells stimulated with H2O2. Microvascular dysfunction is 
manifestation of reperfusion injury and is characterized by endothelial 
cell dysfunction which causes vasoconstriction and increased ROS 
production [10-12]. Platelet gel reduced the amount of ROS produced 
in response to H2O2 in HUV-EC cells suggesting that one mechanism 
used by platelet gel to enhance left ventricular heart function may be to 
reduce ROS production in the microvascular in response to ischemia 
and reperfusion, thereby decreasing vasoconstriction of the coronary 
vessels. It has been known for some time that that ROS generated 
during reperfusion participates in myocardial stunning and that anti-
oxidants reduce ROS stunning [13]. The controversy regarding whether 
antioxidants reduce infarct size is still a major question. There are 
investigators that feel antioxidants reduce infarct size [14-16] while 
others find no reduction in infarct size with antioxidant use [17-19]. 
Our in vitro data show that platelet gel reduces ROS formation in HUV-
EC and H9c2 cells. Therefore, a reduction in ROS, would be beneficial 
to preserving non necrotic heart tissue and reducing infarct size. For 
further analysis, the content of the ns-PRP supernatant was separated 
with HPLC size exclusion chromatography and the entire eluate 
collected into 0.6 ml fractions as described in Materials and Methods. 
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Figure 3: Efficacy of ns-PRP and the ns-PRP supernatant on ROS formation 
in HUV-EC cells in the presence and absence of H2O2.  The cells were loaded 
with 20 µM concentration of CM-H2DCFDA dye solution designed to detect 
ROS generation using flow cytometry.  * compares ROS generation in HUV-EC 
cells in culture  pretreated with fresh nsPEF-PRP and stimulated with 0.15% 
H2O2; p<0.013. ** compares ROS generation in HUC-EC cells  pretreated with 
fresh nsPEF-PRP supernatant and stimulated with 0.15% H2O2; p<0.009. Data 
are stated as mean ± SD. N=number of separate experiemnts.
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Figure 4: Protein separation in PRP sample, induced with 300 ns pulses. 
Protein separation was performed using Gel filtration HPLC 10/300 Superdex 
200 column (GE Healthcare). 1 ml of the sample was loaded onto column and 
eluted in Assay Buffer at flow rate 0.6 ml/min.  The fractions collected between 
11-14 ml of elution volume ( left shadowed box)  and 15-18 ml of elution volume 
(right shadowed box) demonstrated anti-ROS enzymatic activity specific for 
catalase and superoxide dismutase correspondently. 
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Gel filtration column elution profile is depicted in Figure 4. Inhibition 
of H2O2 -derived ROS production and mitochondrial depolarization in 
HUV-EC cells were found in the fractions collected between 11-14 ml 
of elution volume (left shadowed box) and 15-18 ml of elution volume 
(right shadowed box). Suspecting that eluted molecules should be in 
a range between 100-400 kDa and 14-40 kDa we hypothesized that 
catalase (CAT, 240 kDa) and superoxide dismutase (SOD, 32.5 kDa) 
may be responsible for anti-oxidative properties of ns-PRP supernatant. 
The fractions from active regions were analyzed with enzyme specific 
assays for catalase and superoxide dismutase as described in Materials 
and Methods. Enzymatic activity for catalase was found in fractions 12-
16 (Figure 5A), which collected between 11-14 ml of elution volumes. 
Enzymatic activity for SOD was found in fractions 21-23 (Figure 5B) 
which collected between 15-18 ml of elution volumes. In contrast to 
ns-PRP, matching regions of t-PRP derived eluate retained very minor 
activity for both enzymes (Figures 5A and 5B). We quantified enzymatic 
activity in PRP samples that were not processed with HPLC. Again there 
was a significantly greater activity of catalase (p<0.003) (Figure 6A) and 
superoxide dismutase (p<0.002) (Figure 6B) in the PRP supernatant 
made with nsPEFs when compared to the PRP supernatant prepared 
using bovine thrombin. The data show that the method used to prepare 
PRP can influence its contents and may account for, at least in part, 
why some investigators report a lack of response to platelet gel prepared 
using bovine thrombin as the platelet activator.
Secondly, platelet gel appears to protect the mitochondria in both 
H9c2 [4] and HUV-EC cells in vitro (Figure 2). The paradox with these 
results is that mitochondria are both a source of ROS via the electron 
transport chain during electron transport at complexes I and III and 
a target for ROS damage [20]. The flow of electrons down the chain 
in the mitochondria is inhibited by ischemia and is associated with a 
number of other changes such as a reversal of the role of the proton-
translocating enzyme FoF1ATP synthase. This enzyme which normally 
produces ATP now consumes ATP which is used to pump protons 
from the matrix into the inter-membrane space [20,21]. These changes 
ultimately lead to elevated cytosolic calcium and activation of proteins 
which can degrade enzymes such as nucleases, phospholipases and 
proteases, leading to destruction of the membrane integrity [22,23]. 
During reperfusion, a decrease in pH, calcium overload and increased 
oxidative stress can cause the opening of large conductance transition 
pores (mPTP) which can change the membrane potential of the 
mitochondria. There is a positive correlation between mitochondrial 
membrane potential and production of ROS by electron transport 
[20]. Implying that the greater the change in mitochondrial membrane 
potential the more ROS is produced or vice versa. Nevertheless, our 
data suggest that platelet gel may alter this relationship. We show that 
pretreatment with platelet gel significantly reduces mitochondrial 
depolarization in HUV-EC (Figure 2) and in H9c2 cells [4], in vitro. 
This is in addition to the changes in ROS we described earlier. These 
data suggest that platelet gel may provide a degree of protection to 
mitochondria in heart and endothelial cells under oxidative stress 
thereby reducing ROS generation. The mechanism used by platelet gel 
to protect mitochondria from damage is unclear and currently under 
investigation in our laboratory. 
Thirdly, we investigated the effect of platelet gel on metalloproteinases 
and their inhibitors in H9c2 cells using Western Blot analysis. In the 
heart, activation of MMPs triggers cardiac myocyte necrosis and left 
ventricle dysfunction and promotes adverse left ventricle remodeling 
[24]. Matrix metalloproteinase (MMP-2) is a zinc dependent 
endopeptidase that plays a detrimental role in ischemia and reperfusion 
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Figures 5A and B: Enzymatic activity for catalase was found in fractions 12-
16 (Figure 5A), which collected between 11-14 ml of elution volumes (n=3 
separate assays).  Enzymatic activity for superoxide dismutase was found 
in fractions 21-23 (Figure 5B) which collected between 15-18 ml of elution 
volumes (n=3 separate assays).  In contrast to ns-PRP, matching regions of 
the bovine thrombin ( t-PRP)  derived eluate retained very minor activity for 
both enzymes (Figures 5A and 4B).  
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Figures 6A and B: Representative  examples of the  changes in the 
concentration of MMP-2 and TIMP-1 in H9c2 cells in culture in the presence 
or absence of platelet gel made using nsPEFs and stimulated with 1% H2O2 
(n=4). Platelet gel decreased MMP-2 and increased TIMP-1 when stimulated 
with H2O2.. 
--
---
I • .J!!i ... _ --
--
1000 
f 800 
C 
E 
°5 600 
E 
.s 
i:' 
·, 400 ~ 
.... 
~ 200 
Catalase Activity In PRP Supernatant Prepared With 
nsPEF or Bovine Thrombin 
* 
'p<0.003 
nsPEF PRP 
Supernatant 
Bovine Thrombin 
PRP Supernatant 
Superoxide Disrnutase Aclivy in PRP 
Supernatant Prepared Using 
nsPEF or Bovine Thrornbin 
'p<0.002 
* 
nsPEF-PRP 
Supernatant 
Bovine Thrornbin-PRP 
Supernatant 
Citation: Hargrave BY (2014) Autologous Platelet Rich Plasma (Platelet Gel): An Appropriate Intervention for Salvaging Cardiac Myocytes under 
Oxidative Stress after Myocardial Infarction. Anat Physiol 4: 134. doi:10.4172/2161-0940.1000134
Page 7 of 8
Volume 4 • Issue 1 • 1000134Anat PhysiolISSN:2161-0940 Physiol, an open access journal 
injury of the heart. In addition, MMP-2 degrades cardiac contractile 
proteins in response to increased oxidative stress [25,26]. The baseline 
level of MMP-2 was 35 fold greater than TIMP-1. When H9c2 cells were 
treated with platelet gel there was a 98% decrease in MMP-2 and a 600% 
increase in TIMP-1. When the cells were stimulated with hydrogen 
peroxide there was no increase in MMP-2 but TIMP-1 decreased slightly 
but did not return to baseline. We also measured MMP-9, and TIMP-4 
but could not show a change from baseline in these proteases. MMP-2 
and MMP-9 are inactivated by TIMP-1 and TIMP-2 [27]. Loss of the 
coordinated expression of MMPs and TIMPs is believed to generate 
tissue degradation under inflammatory conditions. One mechanism 
that may be used by platelet gel to reduce or prevent further damage 
to the myocytes after ischemia and reperfusion is to coordinate the 
ratios of MMPs and TIMPs. In support of this concept we showed that 
platelet gel prepared using nsPEFs had significantly greater amounts of 
the endogenous antioxidants catalase and superoxide dismutase than 
the gel prepared using thrombin. These data suggest 2 important points: 
1) that the greater concentration of catalase and superoxide dismutase 
in the ns-PRP may account for, at least in part, why the Langendorff 
hearts treated with the platelet gel made using nsPEFs performed better 
in terms of work function than the hearts treated with platelet gel made 
with thrombin or with treated with BSA. 2) thrombin may interfere 
with the function of the platelet gel by reducing the concentration of 
endogenous antioxidants. Although thrombin is considered to be the 
“gold standard” for platelet activation, many of the principal actions of 
thrombin may be harmful to the heart. Thrombin is a multifunctional 
protease, which is pro-apoptotic and pro-inflammatory [28] and may 
have adverse effects on cardiac myocytes, which are independent of 
its pro-coagulant activity [28,29]. It has been shown that in humans, 
thrombin generation during reperfusion after coronary artery bypass 
surgery is associated with postoperative myocardial damage [30,31] 
and that its thrombotic activity is only partially suppressed by heparin 
[29]. Other investigators have shown that while PRP has the potential 
to increase the osteo-inductivity of demineralized bone matrix, its 
activation with bovine thrombin immediately prior to implantation 
significantly inhibits this activity [32], again, suggesting that thrombin 
may interfere with the efficacy of PRP. Finally, thrombin has been 
shown to cause the generation of ROS [31]. 
There are some aspects of this study that may appear as limitations 
such as the small sample size. We do not view this as a limitation 
because one goal of the investigator was to use the least number of 
animals possible to provide statistically significant data a fact that is 
expected of each investigator by the Old Dominion University IACUC. 
We show statistically significant data in our Langendorff hearts treated 
with platelet gel prepared using nsPEFs versus platelet gel made with 
bovine thrombin or with bovine serum albumin (control). To simply 
increase the number of animals for the purpose of having a large “n” is 
unethical and was not performed by this investigator. We view the use 
of animals in research as a privilege and not a right so we strive to use 
as few animals as possible to get statistically significant data. Another 
possible limitation may be that an asanguinous isolated preparation 
(Langendorff heart model) was used, asking the question whether 
similar results would be realized if blood (rather than Tyrodes media) 
was perfused through the heart. We answer this concern by noting that 
we have performed similar studies using the rabbit heart in vivo and 
show similar results i.e. that hearts treated with platelet gel perform 
better than hearts treated with our control [4]. Lastly, one may consider 
the calculation of work function a rudimentary measurement of LV 
function. While we admit that there are more sophisticated equipment 
that could be used by studies performed with large financial budgets, 
the results were the same regarding the improvement in left ventricular 
function in hearts treated with platelet gel whether we used a balloon 
catheter (which was used in this study) or a Millar catheter which was 
used previously [4]. 
In summary, we propose a safe, non-chemical, economically 
feasible and effective Intervention for salvaging cardiac myocytes 
under oxidative stress after myocardial infarction and after blood flow 
to the ischemic heart has been restored. There are several procedures 
available to the clinical community for the restoration or reperfusion 
of coronary blood flow which include coronary artery bypass grafting, 
thrombolysis and or percutaneous coronary intervention. However, 
we strongly agree with the sentiments voiced by Bolli et al. who state 
that the field of cardio-protection in acute MI, cardiac surgery and 
cardiac arrest is at a crossroads [33]. A very important point made 
by these investigators is that treatments designed to protect the heart 
from a basic research level are often inefficient34 and expensive from 
a therapeutic and pharmacological standpoint. The results from our 
study provide evidence for a non-chemical, safe, relatively inexpensive 
and effective method to bridge the gap between the restoration of blood 
flow and salvaging non-lethal ischemic heart tissue, thereby preventing 
enlargement of infarct size and possibly reducing remodeling of the 
heart. The use of platelet gel is an autologous process that only requires 
the isolation and activation of platelets whose releasates contain most, if 
not all, factors present to 1) reduce further ROS formation by preserving 
and/or increasing the concentration of endogenous antioxidants, 2) 
reduce injury to mitochondria, thus protecting the energy source for 
the heart 3) reduce the concentration of proteases activated by ischemia 
and reperfusion designed to degrade components of the extracellular 
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Figures 7A and B:  Representative examples of changes in TIMP-1 (Figure 
7A-Tissue Inhibitor Metalloproteinase-1) and MMP-2 (Figure 7B-Tissue 
Metalloproteinase-2 ) using Western Blot Analysis  in the presence or absence 
of platelet gel made using nsPEFs and stimulated with 1% H2O2 (n=4). Platelet 
gel decreased MMP-2 and increased TIMP-1 when stimulated with H2O2.
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matrix (MMP-2) of the heart and to increase the inhibitory proteases 
designed to prevent or control this degradation (TIMP-1). 
In conclusion we provide evidence for the use of an old agent/
concept (activated platelet supernatant) in a new paradigm that 
addresses a clinically relevant outcome (reduction in damage to the 
ischemic reperfused heart) in addition to some of its mechanisms 
action.
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